Longeveron (LGVN) investor relations material

Executive summary

• Secured $15 million in new capital from institutional investors, with a potential additional $15 million pending milestones, to support ongoing operations and clinical development.

• Focused on advancing pivotal clinical trials in HLHS and PDCM, with HLHS program nearing pivotal phase 2b data readout in Q3 2026 and potential for first BLA submission.

• Actively exploring licensing and partnership opportunities for Alzheimer's disease, age-related frailty, and female sexual dysfunction programs.

• Appointed Stephen H. Willard as CEO in February 2026, bringing extensive biotech leadership experience.

• Implemented cash-saving measures in early 2026 to extend cash runway.

Financial highlights

• 2025 revenues were $1.2 million, down 50% from $2.4 million in 2024, due to lower demand for clinical trials and contract manufacturing.

• General and administrative expenses rose 17% to $12 million, and research and development expenses increased 48% to $12 million.

• Net loss widened to $22.7 million in 2025 from $16 million in 2024, a 41% increase.

• Gross profit for 2025 was $0.8 million, a 57% decrease from $1.9 million in 2024.

• Cash and equivalents at year-end 2025 were $4.7 million; a $15.9 million private placement in March 2026 extended runway into Q4 2026.

Outlook and guidance

• Anticipates reporting pivotal ELPIS II trial results for HLHS in Q3 2026 and targeting BLA submission in 2027.

• Plans to initiate PDCM phase 2 trial in 2027, with feasibility assessments in 2026.

• Strategic focus on securing partnerships and non-dilutive funding for Alzheimer's and frailty programs in 2026.

• Existing cash and proceeds from the private placement expected to fund operations into Q4 2026.

• Focus on robust partnering strategy to accelerate development and commercialization across programs.